A Study of Advanced or Metastatic Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to evaluate the efficacy and safety of LY2603618 in combination with pemetrexed and any side effects that might be associated with it along with determining the effects of LY2603618 in combination with pemetrexed in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Pemetrexed

Criteria

Inclusion Criteria:

• Must agree to have a tumor biopsy at screening

• Must have a diagnosis of advanced or metastatic non-squamous non-small cell lung cancer that has progressed after certain prior treatment

• Must be available for the duration of the study and willing to follow the study procedures

• If participant is a woman that is capable of having children, must have a negative pregnancy test within 7 days of taking first dose of study drug

• Must have discontinued radiation therapy at least 4 weeks before entering this study

Exclusion Criteria:

• Must not have taken an unapproved drug as treatment for any indication within the last 28 days before starting study treatment.

• Must not be pregnant or lactating, are considering becoming pregnant, or are considering fathering a child. Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial until the participant's physician considers it safe to become pregnant or father a child.

• Must not have known positive test in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb).

• Must not have previously participated in a study involving LY2603618

• Must not have previously taken pemetrexed for cancer

• Must not have a known allergy to LY2603618 or pemetrexed

• Must not currently have an infection that may affect participant's ability to tolerate the therapy

• Must not have a serious medical condition or disorder that would make it unsafe for you to participate in the study such as uncontrolled diabetes or chest pain due to heart disease

• If taking certain medications called non-steroidal anti-inflammatory drugs (NSAIDS), such as ibuprofen, must be able to stop taking these medications according to certain guidelines